 RED BANK, N.J., Sept. 13, 2021 PRNewswire -- Provention Bio, Inc. Nasdaq: PRVB, a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update on the status and timing of its ongoing efforts to address FDA considerations cited in the Complete Response Letter CRL issued to the Company by the FDA on July 2, 2021. 